corp_html/html/Azithromycin2.htm

<p><b>The PLIVA - Pfizer Partnership</b></p>
<p>PLIVA selected Pfizer as a strategic and licensing partner because of Pfizer's 
  overall capabilities and track record, and because of its international presence 
  and sales force which complemented PLIVA's presence in Central and Eastern Europe 
  and the former Soviet Union. Additionally, Pfizer had a clear understanding 
  of azithromycin as a result of its own research into macrolides.</p>
<p>Under the agreement, Pfizer and PLIVA agreed to a territorial division of exclusive 
  rights to sell azithromycin dosage forms. PLIVA maintains the right to sell 
  its Sumamed in Central and Eastern Europe as well as some other countries (e.g. 
  People's Republic of China). Royalties from the sales of Zithromax, Pfizer's 
  branded version of azithromycin, in Pfizer's territory are paid to PLIVA. For 
  PLIVA, a small pharmaceutical company when compared to its licensee Pfizer, 
  the azithromycin licensing agreement meant a huge breakthrough in terms of annual 
  revenues and these allowed PLIVA to expand its research activities.</p>
1	<p><b>The PLIVA - Pfizer Partnership</b></p>
2	<p>PLIVA selected Pfizer as a strategic and licensing partner because of Pfizer's
3	overall capabilities and track record, and because of its international presence
4	and sales force which complemented PLIVA's presence in Central and Eastern Europe
5	and the former Soviet Union. Additionally, Pfizer had a clear understanding
6	of azithromycin as a result of its own research into macrolides.</p>
7	<p>Under the agreement, Pfizer and PLIVA agreed to a territorial division of exclusive
8	rights to sell azithromycin dosage forms. PLIVA maintains the right to sell
9	its Sumamed in Central and Eastern Europe as well as some other countries (e.g.
10	People's Republic of China). Royalties from the sales of Zithromax, Pfizer's
11	branded version of azithromycin, in Pfizer's territory are paid to PLIVA. For
12	PLIVA, a small pharmaceutical company when compared to its licensee Pfizer,
13	the azithromycin licensing agreement meant a huge breakthrough in terms of annual
14	revenues and these allowed PLIVA to expand its research activities.</p>